Information for Scientific Collaborators

	Research Collaboration: Procedures and Guidelines
	Orientation Document (study design, data collection, future data analysis, publications)
	Full Text of Questionnaires
	Phase 1 User Manual
	Phase 2 User Manual
	General File User Manual
	Data File Requests
	Advisory Panel Members
	Overview of Agricultural Health Study Data
	Usage Notes Pertaining to P1-P2 Analysis File

Cancer incidence and mortality data on the cohort are being obtained from cancer registries within Iowa and North Carolina and state vital statistics offices on a yearly basis. In addition, mortality data on the cohort is being obtained every other year from the National Death Index (NDI). Cancer incidence in the cohort is presented in Table 2 and mortality in the cohort is presented in Tables 3.

Table 2a: Post-enrollment (Incident only) Malignant Cancer Cases by Site and Phase II Data Collection progress ^1,2,3

	Incident Cases Only
Cancer Site	Total with Cancer	Completed Phase II	Returned Buccal Sample	Returned DHQ
Bladder	237	144	103	98
Brain	75	27	18	19
Breast	747	577	404	424
Bronchus and Lung	593	276	147	157
Colon	515	321	209	200
Head and Neck	58	27	17	14
Kidney and Renal Pelvis	187	103	71	68
Leukemia	174	93	64	56
Liver and Intrahepatic Bile Ducts	47	18	8	11
Melanoma	270	187	122	126
Mesothelioma	14	4	3	1
Multiple Myeloma	92	58	38	42
NHL	281	169	112	118
Oral	110	77	53	51
Other	465	264	163	168
Ovary	73	54	31	33
Pancreas	114	55	23	29
Prostate	1,658	1,127	1,068	742
Rectum and Rectosigmoid Junction	207	130	83	87
Stomach	79	47	37	34
Thyroid Gland	94	61	42	40
Uterine	168	121	78	84
Total	6,258	3,940	2,894	2,602

Table 2b: Pre- and Post-enrollment (Prevalent and Incident) Malignant Cancer Cases by Site and Phase II Data Collection progress ^1,2,3

	Prevalent Plus Incident Cases
Cancer Site	Total with Cancer	Completed Phase II	Returned Buccal Sample	Returned DHQ
Bladder	319	191	134	125
Brain	94	39	25	26
Breast	1,202	919	636	676
Bronchus and Lung	638	293	157	169
Colon	658	405	274	258
Head and Neck	76	37	24	21
Kidney and Renal Pelvis	226	127	87	81
Leukemia	229	125	85	80
Liver and Intrahepatic Bile Ducts	49	19	9	12
Melanoma	397	275	177	187
Mesothelioma	14	4	3	1
Multiple Myeloma	103	62	42	45
NHL	384	225	152	164
Oral	166	114	78	78
Other	634	373	230	239
Ovary	122	90	59	59
Pancreas	125	58	23	30
Prostate	2,085	1,393	1,234	938
Rectum and Rectosigmoid Junction	292	181	123	125
Stomach	86	49	38	35
Thyroid Gland	189	136	94	92
Uterine	260	189	117	132
Total	8,348	5,304	3,801	3,573

¹ Cancer counts are based on nearly complete registry data through 2005.
² Subjects previously diagnosed with cancer at a different site are included.
³ Buccal cell receipts represent progress through 2007.
⁴ The 'Other' category includes in-situ bladder cancers.
⁵ SEER Site Recode ICD-O-3 (1/27/2003) Definition used for classifying cancers.

Table 3: Cause Specific Mortality of AHS Cohort, 1994-2007

Cause	Frequency	Percent	Cumulative Frequency	Cumulative Percent
Accidents	370	6.50	370	6.50
Cancer	2,050	36.00	2.420	42.49
Cerebrovascular Disease	295	5.18	2,715	47.67
Diabetes Mellitus	124	2.18	2,839	49.85
Heart Disease	1,613	28.32	4,452	78.17
Respiratory Disease	363	6.37	4,815	84.55
Other	880	15.45	5,695	100.00

Table 4: Medical Conditions ¹ (fully expanded)

	Private Applicators	Spouses	Commercial Applicators	Total
Number in Cohort:	N=52,395	N=32,347	N=4,916	N=89,658
Category	Count	Count	Count
Completed Phase II Questionnaire	33,457	23,796	2,885	60,138
Cardiovascular Disease    Heart Attack (Myocardial Infarction) 1,789 370 122 2,281    Irregular Heart Beat (Arrhythmia) 3,267 2,571 243 6,081    High Blood Pressure or Hypertension 8,637 5,954 870 15,461
Endocrine Disorder    Diabetes or High Blood Sugar 2,429 1,314 188 3,931    Thyroid Disease or Thyroid Problems 1,075 2,947 90 4,112    Overactive Thyroid (Hyperthyroidism) 279 659 N/A 4 N/A    Graves Disease 62 151 N/A 4 N/A    Underactive Thyroid (Hypothyroidism) 528 1,792 55 2,375    Thyroiditis, Hashimoto's Disease, Autoimmune Disease 31 212 N/A 4 N/A    Enlarged Thyroid, Thyroid Nodules, Goiter 204 997 N/A 4 N/A    Other Thyroid Problem 113 169 N/A 4 N/A
Women's Health Disorder      Endometriosis N/A 2 1,694 N/A 2 N/A    Uterine Fibroids N/A 2 3,514 N/A 2 N/A    Benign Breast Disease (Fibroids, Cysts, Other) N/A 2 4,060 N/A 2 N/A    Pregnancy Induced High Blood Pressure,    Pre-Eclampsia, Toxemia or Eclampsia N/A 2 103 N/A 2 N/A    Gestational Diabetes N/A 2 77 N/A 2 N/A
Autoimmune/Musculoskeletal Disorders    Rheumotoid Arthritis N/A 2 908 N/A 2 N/A    Lupus (SLE) N/A 2 110 N/A 2 N/A    Sjogren's Disease N/A 2 43 N/A 2 N/A    Scleroderma or Systemic Sclerosis N/A 2 32 N/A 2 N/A
Kidney Disorder    Kidney Stones 3,862 1,279 200 5,341    Kidney Disease or Kidney Failure 354 214 28 596
Digestive Disorder    Inflammatory Bowel Disease    (Chron's Disease, Ulcerative Colitis) 430 514 41 985
Skin Disorder    Vitiligo 130 84 N/A 4 N/A    Eczema 719 1,124 89 1,932    Psoriasis 821 582 76 1,479    Allergy to Bees, Wasps, or Other Insects 1,735 1,120 158 3,013
Optical or Hearing Disorder    Blindness 619 N/A 3 36 N/A    Nearsightedness 12,237 N/A 3 1,345 N/A    Farsightedness 13,683 N/A 3 1,217 N/A    Cataracts 3,427 N/A 3 199 N/A    Glaucoma 680 N/A 3 49 N/A    Detached Retina 358 N/A 3 30 N/A    Retinal or Macular Degeneration 391 N/A 3 34 N/A    Hearing Problems 11,781 N/A 3 913 N/A
Injury    Head Injury 6,623 1,556 726 8,905    Neck, Back, Spinal Cord Injury 6,250 2,198 588 9,036    Post-Polio Syndrome, Leg Injury 4,344 1,474 188 6,006
Neurologic Disorder    Epilepsy 123 127 N/A 4 N/A    Multiple Sclerosis 39 83 N/A 4 N/A    Parkinson's Disease 89 29 N/A 4 N/A    Tremor (Essential, Familial, Benign) 144 113 N/A 4 N/A

¹ Numbers represent medical conditions reported during Phase II interviews. Because the asking of some questions was dependent on responses to earlier questions, the counts in this table reflect the numbers of each condition reported but not the total occurrence of the diseases in the cohort.
² These conditions marked with N/A were not asked about in the men's health questions. Since 96 percent of private applicators and commercial applicators in the cohort are men, it would be misleading to report counts for these conditions in the private applicator column.
³ Hearing problems were not asked about in the women's health questions. Since 99.5 percent of spouses in the cohort are women, it would be misleading to report hearing problem counts in the spouse column.
⁴ These conditions occur in commercial applicators in insufficient numbers to be reported at this time.